Cite
HARVARD Citation
Andrew, D. et al. (n.d.). P-287Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): a randomized, open-label phase 2 study. Annals of oncology. p. ii84. [Online].